TABLE 1.
Pathogenicity of VSV and vVSV
| Virus | No. of mice with symptoms/no. in group
|
||||
|---|---|---|---|---|---|
| After 1st infection | After 2nd infection | After challenge with Zaire Ebola virus | No. of survivors at day 28 after challenge | Mean time to death (days) | |
| None (naïve controls) | N/Aa | N/A | 4/4 | 0/4 | 5.8 |
| Wild-type VSV | 0/5 | 0/5 | 5/5 | 0/5 | 5.5 |
| VSVΔG/LASVGPC | 0/5 | 0/5 | 5/5 | 0/5 | 7.2 |
| VSVΔG/MARVGP | 0/5 | 0/5 | 5/5 | 0/5 | 6.6 |
| VSVΔG/ZEBOVGP | 0/5 | 0/5 | 0/5 | 5/5 | N/A |
| Gamma-irradiated VSVΔG/EBOVGP | 0/5 | 0/5 | 5/5 | 0/5 | 7 |
| VSV/ZEBOVsGP | 0/5 | 0/5 | N/Db | N/D | N/A |
| VSV/MARVGP1 | 0/5 | 0/5 | N/D | N/D | N/A |
a
N/A, not applicable.
b
N/D, not determined.